Aktie A401XM MYMD PHARMACEUTICALS, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen MyMD Pharmaceuticals, Inc.

Aktien

A401XM

US62856X2018

MYMD

Markt geschlossen - Nasdaq
Andere Börsenplätze
 22:00:00 30.04.2024 		% 5 Tage % 1. Jan.
3,08 USD +6,21 % Intraday Chart für MyMD Pharmaceuticals, Inc. +20,31 % -60,31 %
18.04. MyMD Pharmaceuticals, Inc. gibt den Rücktritt von Adam Kaplin als Chief Scientific Officer bekannt CI
09.04. Wall Street eröffnet leicht höher, da die Anleger die Inflationsdaten vom Mittwoch erwarten MT

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
MyMD Pharmaceuticals, Inc. Announces Resignation of Adam Kaplin as Chief Scientific Officer
Ladenburg Thalmann, Esteemed Wall Street Long-Standing Stalwart Since 1876, Advocates 'Buy' for Intelligent Bio, Precision Bio, and More: VTAK, INBS, LASE, MYMD, RVSN
Wall Street Set to Open Slightly Higher as Investors Await Wednesday's Inflation Data
Investors Eye Wednesday Inflation Data as US Futures Tread Water Tuesday Pre-Bell
Top Premarket Gainers
MyMD Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
MyMD Pharmaceuticals Regains Compliance With Nasdaq's Minimum Bid Listing Requirement
MyMD Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing
MyMD Pharmaceuticals to Implement 1-for-30 Reverse Stock Split
MyMD Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing
MyMD Pharmaceuticals Plans FDA-Cleared Phase 2 Clinical Trial of MYMD-1 in Rheumatoid Arthritis
MyMD Pharmaceuticals, Inc. Plans FDA-Cleared Phase 2 Clinical Trial of MYMD-1 in Rheumatoid Arthritis
MyMD Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Developing a first-in-class small molecule drug for inflammatory disease
MyMD Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD, Reduced Acute Inflammatory Pain
MyMD Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD™, Reduced Acute Inflammatory Pain
Mymd Pharmaceuticals, Inc. Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD, Reduced Acute Inflammatory Pain
MyMD Pharmaceuticals to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF- Market Disrupter, at BioFuture 2023
MyMD Pharmaceuticals to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF-α Market Disrupter, at BioFuture 2023
MyMD Pharmaceuticals, Inc. to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF-a Market Disrupter, at BioFuture 2023
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A401XM Aktie
  4. Nachrichten MyMD Pharmaceuticals, Inc.
  5. Andere Sprachen